| KEGG pathways enriched for interacted genes |
| pathway name | pathway description | target genes enrich in pathway | p-value |
|
|
hsa05212
|
Pancreatic cancer |
CASP9,TGFB1,VEGFA,BCL2L1,EGFR,TGFBR2,CDC42,PIK3R2, |
6.01E-8 |
|
hsa05200
|
Pathways in cancer |
IGF1R,CASP9,TGFB1,GSTP1,VEGFA,BCL2L1,EGFR,TGFBR2,CDC42,PIK3R2, |
2.87E-5 |
|
hsa05210
|
Colorectal cancer |
IGF1R,CASP9,TGFB1,EGFR,TGFBR2,PIK3R2, |
6.61E-5 |
|
hsa04510
|
Focal adhesion |
IGF1R,VEGFA,EGFR,COL1A1,CCND2,CDC42,PIK3R2, |
5.22E-4 |
|
hsa04370
|
VEGF signaling pathway |
CASP9,VEGFA,NFATC4,CDC42,PIK3R2, |
5.92E-4 |
|
|
|
hsa04350
|
TGF-beta signaling pathway |
TGFB1,PPP2R1A,PPP2R1B,TGFBR2,SP1, |
1.03E-2 |
|
hsa05215
|
Prostate cancer |
IGF1R,CASP9,GSTP1,EGFR,PIK3R2, |
1.13E-2 |
|
hsa04010
|
MAPK signaling pathway |
SRF,TGFB1,NFATC4,EGFR,CACNA1C,TGFBR2,CDC42, |
2.30E-2 |
|
hsa05211
|
Renal cell carcinoma |
TGFB1,VEGFA,CDC42,PIK3R2, |
5.76E-2 |
|
hsa05220
|
Chronic myeloid leukemia |
TGFB1,BCL2L1,TGFBR2,PIK3R2, |
6.99E-2 |
|
hsa04520
|
Adherens junction |
IGF1R,EGFR,TGFBR2,CDC42, |
7.51E-2 |
|
hsa04144
|
Endocytosis |
IGF1R,HLA-G,EGFR,TGFBR2,CDC42, |
1.51E-1 |
|
hsa04930
|
Type II diabetes mellitus |
CACNA1C,PKM2,PIK3R2, |
2.53E-1 |
|
hsa04810
|
Regulation of actin cytoskeleton |
ARPC5,MSN,EGFR,CDC42,PIK3R2, |
2.53E-1 |
|
hsa05213
|
Endometrial cancer |
CASP9,EGFR,PIK3R2, |
3.05E-1 |
|
hsa05223
|
Non-small cell lung cancer |
CASP9,EGFR,PIK3R2, |
3.27E-1 |
|
hsa05214
|
Glioma |
IGF1R,EGFR,PIK3R2, |
4.34E-1 |
|
hsa04310
|
Wnt signaling pathway |
NFATC4,PPP2R1A,CCND2,PPP2R1B, |
4.45E-1 |
|
hsa04730
|
Long-term depression |
IGF1R,PPP2R1A,PPP2R1B, |
5.12E-1 |
|
hsa05218
|
Melanoma |
IGF1R,EGFR,PIK3R2, |
5.39E-1 |
|
hsa05222
|
Small cell lung cancer |
CASP9,BCL2L1,PIK3R2, |
7.25E-1 |
|
hsa05410
|
Hypertrophic cardiomyopathy (HCM) |
TGFB1,TPM1,CACNA1C, |
7.40E-1 |
|
hsa04210
|
Apoptosis |
CASP9,BCL2L1,PIK3R2, |
7.70E-1 |
|
hsa05414
|
Dilated cardiomyopathy |
TGFB1,TPM1,CACNA1C, |
8.48E-1 |
|
hsa04666
|
Fc gamma R-mediated phagocytosis |
ARPC5,CDC42,PIK3R2, |
8.96E-1 |
|
hsa04912
|
GnRH signaling pathway |
EGFR,CACNA1C,CDC42, |
9.45E-1 |
|
|
|
|
|
|
|
| Gene ontology terms enriched for interacted genes |
| GO terms | GO terms description | target genes enrich in GO term | p-value |
|
|
GO:0010033
|
response to organic substance |
VKORC1,IGF1R,SRF,TGFB1,BCL2L1,EGFR,NR4A2,PPP2R1A,COL1A1,CCND2,TGFBR2,MCL1, |
5.05E-5 |
|
GO:0009719
|
response to endogenous stimulus |
VKORC1,IGF1R,SRF,TGFB1,BCL2L1,NR4A2,COL1A1,CCND2,TGFBR2, |
1.07E-4 |
|
GO:0044057
|
regulation of system process |
SRF,TPM1,KCNH2,KCNQ1,HCN4,EGFR,CACNA1C,BCAN, |
1.30E-4 |
|
GO:0006936
|
muscle contraction |
TPM1,KCNH2,KCNQ1,HCN2,HCN4,CACNA1C, |
2.43E-4 |
|
GO:0019725
|
cellular homeostasis |
SRF,TGFB1,KCNH2,KCNQ1,HCN2,BCL2L1,CACNA1C,FTL,MCL1, |
2.80E-4 |
|
|
|
GO:0042592
|
homeostatic process |
SRF,TGFB1,VEGFA,KCNH2,KCNQ1,HCN2,BCL2L1,CACNA1C,SP1,FTL,MCL1, |
3.55E-4 |
|
GO:0003012
|
muscle system process |
TPM1,KCNH2,KCNQ1,HCN2,HCN4,CACNA1C, |
3.75E-4 |
|
GO:0030099
|
myeloid cell differentiation |
TGFB1,VEGFA,TGFBR2,SP1,CDC42, |
3.78E-4 |
|
GO:0030334
|
regulation of cell migration |
IGF1R,EGFL7,TGFB1,TPM1,VEGFA,EGFR, |
3.85E-4 |
|
GO:0050679
|
positive regulation of epithelial cell proliferation |
TGFB1,VEGFA,EGFR,CCND2, |
4.58E-4 |
|
GO:0008015
|
blood circulation |
TPM1,VEGFA,KCNH2,KCNQ1,HCN4,CACNA1C, |
5.97E-4 |
|
GO:0003013
|
circulatory system process |
TPM1,VEGFA,KCNH2,KCNQ1,HCN4,CACNA1C, |
5.97E-4 |
|
GO:0040012
|
regulation of locomotion |
IGF1R,EGFL7,TGFB1,TPM1,VEGFA,EGFR, |
6.89E-4 |
|
GO:0051270
|
regulation of cell motion |
IGF1R,EGFL7,TGFB1,TPM1,VEGFA,EGFR, |
7.06E-4 |
|
GO:0008284
|
positive regulation of cell proliferation |
IGF1R,TGFB1,VEGFA,BCL2L1,EGFR,PNP,CCND2,TGFBR2, |
7.65E-4 |
|
GO:0014070
|
response to organic cyclic substance |
VKORC1,TGFB1,BCL2L1,CCND2,TGFBR2, |
1.02E-2 |
|
GO:0043009
|
chordate embryonic development |
SRF,TPM1,BCL2L1,HCN4,COL1A1,TGFBR2,SP1, |
1.31E-2 |
|
GO:0009792
|
embryonic development ending in birth or egg hatching |
SRF,TPM1,BCL2L1,HCN4,COL1A1,TGFBR2,SP1, |
1.37E-2 |
|
GO:0042391
|
regulation of membrane potential |
TGFB1,KCNH2,KCNQ1,HCN2,BCL2L1, |
1.48E-2 |
|
GO:0043066
|
negative regulation of apoptosis |
IGF1R,GSTP1,VEGFA,BCL2L1,EGFR,NR4A2,MCL1, |
1.85E-2 |
|
GO:0042698
|
ovulation cycle |
VEGFA,BCL2L1,EGFR,CCND2, |
1.92E-2 |
|
GO:0043549
|
regulation of kinase activity |
TGFB1,RGS3,EGFR,PPP2R1A,CCND2,TGFBR2,CDC42, |
1.93E-2 |
|
GO:0033993
|
response to lipid |
TGFB1,EGFR,TGFBR2, |
1.97E-2 |
|
GO:0043069
|
negative regulation of programmed cell death |
IGF1R,GSTP1,VEGFA,BCL2L1,EGFR,NR4A2,MCL1, |
1.98E-2 |
|
GO:0060548
|
negative regulation of cell death |
IGF1R,GSTP1,VEGFA,BCL2L1,EGFR,NR4A2,MCL1, |
2.01E-2 |
|
GO:0009725
|
response to hormone stimulus |
IGF1R,SRF,TGFB1,BCL2L1,COL1A1,CCND2,TGFBR2, |
2.22E-2 |
|
GO:0009628
|
response to abiotic stimulus |
CASP9,TGFB1,BCL2L1,EGFR,CACNA1C,COL1A1,TGFBR2, |
2.25E-2 |
|
GO:0050678
|
regulation of epithelial cell proliferation |
TGFB1,VEGFA,EGFR,CCND2, |
2.27E-2 |
|
GO:0051338
|
regulation of transferase activity |
TGFB1,RGS3,EGFR,PPP2R1A,CCND2,TGFBR2,CDC42, |
2.37E-2 |
|
GO:0006873
|
cellular ion homeostasis |
TGFB1,KCNH2,KCNQ1,HCN2,BCL2L1,CACNA1C,FTL, |
2.44E-2 |
|
GO:0042981
|
regulation of apoptosis |
IGF1R,CASP9,TGFB1,GSTP1,VEGFA,BCL2L1,EGFR,NR4A2,PPP2R1A,MCL1, |
2.45E-2 |
|
GO:0048878
|
chemical homeostasis |
TGFB1,VEGFA,KCNH2,KCNQ1,HCN2,BCL2L1,CACNA1C,FTL, |
2.59E-2 |
|
GO:0043067
|
regulation of programmed cell death |
IGF1R,CASP9,TGFB1,GSTP1,VEGFA,BCL2L1,EGFR,NR4A2,PPP2R1A,MCL1, |
2.62E-2 |
|
GO:0055082
|
cellular chemical homeostasis |
TGFB1,KCNH2,KCNQ1,HCN2,BCL2L1,CACNA1C,FTL, |
2.64E-2 |
|
GO:0010941
|
regulation of cell death |
IGF1R,CASP9,TGFB1,GSTP1,VEGFA,BCL2L1,EGFR,NR4A2,PPP2R1A,MCL1, |
2.68E-2 |
|
GO:0043085
|
positive regulation of catalytic activity |
CASP9,TGFB1,TPM1,EGFR,NR4A2,CCND2,TGFBR2,CDC42, |
2.83E-2 |
|
GO:0008016
|
regulation of heart contraction |
TPM1,KCNH2,KCNQ1,HCN4, |
2.86E-2 |
|
GO:0050801
|
ion homeostasis |
TGFB1,KCNH2,KCNQ1,HCN2,BCL2L1,CACNA1C,FTL, |
3.79E-2 |
|
GO:0001701
|
in utero embryonic development |
SRF,TPM1,BCL2L1,HCN4,SP1, |
4.00E-2 |
|
GO:0030335
|
positive regulation of cell migration |
IGF1R,TGFB1,VEGFA,EGFR, |
4.31E-2 |
|
GO:0007010
|
cytoskeleton organization |
ARPC5,TPM1,LASP1,FSCN1,KRT7,CDC42,CNN2, |
5.18E-2 |
|
GO:0044093
|
positive regulation of molecular function |
CASP9,TGFB1,TPM1,EGFR,NR4A2,CCND2,TGFBR2,CDC42, |
5.46E-2 |
|
GO:0040017
|
positive regulation of locomotion |
IGF1R,TGFB1,VEGFA,EGFR, |
5.64E-2 |
|
GO:0051272
|
positive regulation of cell motion |
IGF1R,TGFB1,VEGFA,EGFR, |
5.64E-2 |
|
GO:0048661
|
positive regulation of smooth muscle cell proliferation |
VEGFA,EGFR,TGFBR2, |
5.81E-2 |
|
GO:0009314
|
response to radiation |
CASP9,TGFB1,BCL2L1,EGFR,CACNA1C, |
6.27E-2 |
|
GO:0001501
|
skeletal system development |
TGFB1,EGFR,COL1A1,TGFBR2,SP1,FBN1, |
6.28E-2 |
|
GO:0010035
|
response to inorganic substance |
TPM1,BCL2L1,EGFR,NR4A2,COL1A1, |
6.84E-2 |
|
GO:0006916
|
anti-apoptosis |
IGF1R,GSTP1,VEGFA,BCL2L1,MCL1, |
6.96E-2 |
|
GO:0002573
|
myeloid leukocyte differentiation |
TGFB1,TGFBR2,CDC42, |
6.96E-2 |
|
GO:0042325
|
regulation of phosphorylation |
TGFB1,RGS3,EGFR,PPP2R1A,CCND2,TGFBR2,CDC42, |
7.12E-2 |
|
GO:0007507
|
heart development |
SRF,TPM1,NFATC4,TGFBR2,FBN1, |
8.07E-2 |
|
GO:0019220
|
regulation of phosphate metabolic process |
TGFB1,RGS3,EGFR,PPP2R1A,CCND2,TGFBR2,CDC42, |
8.59E-2 |
|
GO:0051174
|
regulation of phosphorus metabolic process |
TGFB1,RGS3,EGFR,PPP2R1A,CCND2,TGFBR2,CDC42, |
8.59E-2 |
|
GO:0045859
|
regulation of protein kinase activity |
TGFB1,RGS3,EGFR,PPP2R1A,CCND2,TGFBR2, |
8.67E-2 |
|
GO:0001503
|
ossification |
TGFB1,EGFR,COL1A1,SP1, |
8.77E-2 |
|
GO:0051173
|
positive regulation of nitrogen compound metabolic process |
IGF1R,SRF,TGFB1,VEGFA,PRDM16,EGFR,NR4A2,SP1, |
9.01E-2 |
|
GO:0030036
|
actin cytoskeleton organization |
ARPC5,TPM1,FSCN1,CDC42,CNN2, |
9.58E-2 |
|
GO:0001541
|
ovarian follicle development |
VEGFA,BCL2L1,CCND2, |
1.00E-1 |
|
GO:0001570
|
vasculogenesis |
EGFL7,VEGFA,TGFBR2, |
1.00E-1 |
|
|
|
|
|
|
|